nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

13.11.2020 | Hot Topics

Managing Gastrointestinal Complications in Patients With Systemic Sclerosis

verfasst von: Z. H. McMahan, MD, MHS, D. Khanna, MBBS, MSc

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

We sought to critically evaluate the literature published over the past 3 years on the management of gastrointestinal complications in systemic sclerosis (SSc). We emphasize interesting and important new findings to bring the reader up-to-date. We also discuss controversial discoveries and hypotheses currently of interest.

Methods

We conducted a literature search on PubMed over the last 3 years using the keywords “systemic sclerosis,” “gastrointestinal,” “scleroderma,” and “treatment.” We also screened clinicaltrials.gov for ongoing trials relevant to the gastrointestinal complications of SSc. Reference lists from recent reviews on the management of gastrointestinal complications of SSc to identify articles that might have been missed in the initial search.

Results

One hundred three publications and ongoing clinical trials were identified. We eliminated all case reports and review articles. Ultimately, we had 58 articles remaining and we prioritized what we found to be the strongest and/or novel findings to discuss in this review.

Conclusions

Advances in the management of gastrointestinal disease in SSc continue to evolve. The application of novel therapies and the repurposing of existing therapies for the management of gastrointestinal involvement are shaping the therapeutic arsenal so that we can more effectively manage these complex patients.

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. https://doi.org/10.1056/NEJMra0806188.CrossRefPubMed

Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015;1(1):82–105. https://doi.org/10.1007/s40674-014-0005-0.CrossRefPubMedPubMedCentral

Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum. 2005;34(4):689–702. https://doi.org/10.1016/j.semarthrit.2004.08.009.CrossRefPubMed

Dein E, Kuo PL, Hong YS, Hummers LK, Mecoli CA, McMahan ZH. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019;49(3):405–10. https://doi.org/10.1016/j.semarthrit.2019.05.005.CrossRefPubMedPubMedCentral

Volkmann ER, Chang YL, Barroso N, Furst DE, Clements PJ, Gorn AH, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68(6):1483–92. https://doi.org/10.1002/art.39572.CrossRefPubMedPubMedCentral

Marie I, Leroi AM, Gourcerol G, Levesque H, Menard JF, Ducrotte P. Fructose malabsorption in systemic sclerosis. Medicine (Baltimore). 2015;94(39):e1601. https://doi.org/10.1097/MD.0000000000001601.CrossRef

Volkmann ER, Hoffmann-Vold AM. Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur J Rheumatol. 2019:1–8. https://doi.org/10.5152/eurjrheum.2019.19103.

8.••

Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017;4(1):e000134. https://doi.org/10.1136/bmjgast-2017-000134. The first multi-centered study evaluating the GI microbiome in SSc.

Gyger G, Baron M. Systemic sclerosis: gastrointestinal disease and its management. Rheum Dis Clin N Am. 2015;41(3):459–73. https://doi.org/10.1016/j.rdc.2015.04.007.CrossRef

10.••

Kawaguchi Y, Nakamura Y, Matsumoto I, Nishimagi E, Satoh T, Kuwana M, et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis. 2009;68(5):710–4. doi: https://doi.org/10.1136/ard.2008.096545. Important study reporting anti-muscarinic 3 antibodies in SSc patients with severe GI dysmotility.

11.

Kumar S, Singh J, Kedika R, Mendoza F, Jimenez SA, Blomain ES, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1052–60. https://doi.org/10.1152/ajpgi.00034.2016.CrossRefPubMedPubMedCentral

12.

Smirani R, Truchetet ME, Poursac N, Naveau A, Schaeverbeke T, Devillard R. Impact of systemic sclerosis oral manifestations on patients’ health-related quality of life: a systematic review. J Oral Pathol Med. 2018;47(9):808–15. https://doi.org/10.1111/jop.12739.CrossRefPubMed

13.

Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin N Am. 2008;34(1):221–38; ix. https://doi.org/10.1016/j.rdc.2007.10.002.

14.

Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012;32(1):165–8. https://doi.org/10.1007/s00296-010-1595-y.CrossRefPubMed

15.

Braddom CL. The ethics of research. Am J Phys Med Rehabil. 1990;69(3):170–1. https://doi.org/10.1097/00002060-199006000-00012.CrossRefPubMed

16.

Matsuda R, Yamamichi N, Shimamoto T, Sumida H, Takahashi Y, Minatsuki C, et al. Gastroesophageal reflux disease-related disorders of systemic sclerosis based on the analysis of 66 patients. Digestion. 2018;98(4):201–8. https://doi.org/10.1159/000489848.CrossRefPubMed

17.

Strek ME. Systemic sclerosis-associated interstitial lung disease: role of the oesophagus in outcomes. Respirology. 2018;23(10):885–6. https://doi.org/10.1111/resp.13335.CrossRefPubMed

18.

Salaffi F, Di Carlo M, Carotti M, Fraticelli P, Gabrielli A, Giovagnoni A. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. Radiol Med. 2018;123(9):655–63. https://doi.org/10.1007/s11547-018-0894-3.CrossRefPubMed

19.

Furnari M, Savarino V, de Bortoli N, Savarino E. Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev. 2016;15(12):1208–9. https://doi.org/10.1016/j.autrev.2016.09.025.CrossRefPubMed

20.

Smith E, Pauling JD. The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2019;49(1):112–8. https://doi.org/10.1016/j.semarthrit.2018.12.001.CrossRefPubMed

21.

Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, et al. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Sci Rep. 2020;10(1):769. https://doi.org/10.1038/s41598-020-57636-0.CrossRefPubMedPubMedCentral

22.

Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2017;56(2):214–22. https://doi.org/10.1093/rheumatology/kew216.CrossRef

23.

Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther. 2016;18:195. https://doi.org/10.1186/s13075-016-1094-y.CrossRefPubMedPubMedCentral

24.

Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol. 1998;93(7):1085–9. https://doi.org/10.1111/j.1572-0241.1998.00334.x.CrossRefPubMed

25.••

Carbone F, Van den Houte K, Clevers E, Andrews CN, Papathanasopoulos A, Holvoet L, et al. Prucalopride in Gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019;114(8):1265-74. https://doi.org/10.14309/ajg.0000000000000304. The first RCT evaluating the effects of prucalopride in patients with gastroparesis.

26.••

Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19(1):145. https://doi.org/10.1186/s13075-017-1340-y. First study in SSc evaluating the efficacy of prucalopride for lower bowel disease.

27.

Messerli M, Aschwanden R, Buslau M, Hersberger KE, Arnet I. Swallowing difficulties with medication intake assessed with a novel self-report questionnaire in patients with systemic sclerosis - a cross-sectional population study. Patient Prefer Adherence. 2017;11:1687–99. https://doi.org/10.2147/PPA.S142653.CrossRefPubMedPubMedCentral

28.

Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691–712. https://doi.org/10.1111/j.1365-2036.2006.02804.x.CrossRefPubMed

29.

Polkowska-Pruszynska B, Gerkowicz A, Szczepanik-Kulak P, Krasowska D. Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature. Arch Dermatol Res. 2019;311(1):1–8. https://doi.org/10.1007/s00403-018-1874-0.CrossRefPubMed

30.

Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53(5):1163–74. https://doi.org/10.1007/s10620-007-0018-8.CrossRefPubMed

31.

Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008;42(1):5–12. https://doi.org/10.1097/MCG.0b013e318042d625.CrossRefPubMed

32.

Tauber M, Avouac J, Benahmed A, Barbot L, Coustet B, Kahan A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-82-7.

33••.

Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol. 2015;49(7):571-6. https://doi.org/10.1097/MCG.0000000000000257. Important study demonstrating that delayed small bowel transit is associated with bacterial overgrowth.

34.

Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008;103(5):1257–62. https://doi.org/10.1111/j.1572-0241.2007.01758.x.CrossRefPubMed

35.

Manini ML, Camilleri M, Grothe R, Di Lorenzo C. Application of pyridostigmine in pediatric gastrointestinal motility disorders: a case series. Paediatr Drugs. 2018;20(2):173–80. https://doi.org/10.1007/s40272-017-0277-6.CrossRefPubMed

36.

Ahuja NK, Mische L, Clarke JO, Wigley FM, McMahan ZH. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum. 2018;48(1):111–6. https://doi.org/10.1016/j.semarthrit.2017.12.007.CrossRefPubMed

37.

Robinson-Papp J, Nmashie A, Pedowitz E, George MC, Sharma S, Murray J, et al. The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. J Neuro-Oncol. 2019;25(4):551–9. https://doi.org/10.1007/s13365-019-00756-9.CrossRef

38.

Pasha SF, Lunsford TN, Lennon VA. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology. 2006;131(5):1592–6. https://doi.org/10.1053/j.gastro.2006.06.018.CrossRefPubMed

39.••

Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–7. doi: https://doi.org/10.1056/NEJM199111213252102. Landmark paper demonstrating the efficacy of octreotide in SSc patients with intestinaly dysmotility.

40.

H. F, O M, A HT, H D, T G, E B, et al. Fecal microbiota transplantation in patients with systemic sclerosis- a pilot study. Arthritis Rheumatol.2018.

41.

Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. J Rheumatol. 2011;38(9):1920–4. https://doi.org/10.3899/jrheum.110225.CrossRefPubMedPubMedCentral

42.••

Garcia-Collinot G, Madrigal-Santillan EO, Martinez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, et al. Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020;65(4):1134-43. Doi: https://doi.org/10.1007/s10620-019-05830-0. Study demonstrating the benefits of Saccharomyces boulardii treatment in patients in SSc and SIBO.

43.

Brandler JB, Sweetser S, Khoshbin K, Babameto M, Prokop LJ, Camilleri M. Colonic manifestations and complications are relatively under-reported in systemic sclerosis: a systematic review. Am J Gastroenterol. 2019;114(12):1847–56. https://doi.org/10.14309/ajg.0000000000000397.CrossRefPubMed

44.

Battle WM, Snape WJ Jr, Wright S, Sullivan MA, Cohen S, Meyers A, et al. Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med. 1981;94(6):749–52. https://doi.org/10.7326/0003-4819-94-6-749.CrossRefPubMed

45.

Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97(1):194–7. https://doi.org/10.1111/j.1572-0241.2002.05396.x.CrossRefPubMed

46.

Quigley EM. Prokinetics in the management of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2015;21(3):330–6. https://doi.org/10.5056/jnm15094.CrossRefPubMedPubMedCentral

47.

Dein E CJ, Wigley F, McMahan Z. Linaclotide for the treatment of gastrointestinal symptoms in systemic sclerosis [abstract]. Arthritis Rheumatol. 2019;71.

48.

Clark KE, Etomi O, Denton CP, Ong VH, Murray CD. Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S168–70.PubMed

49.

Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016;55(1):115–9. https://doi.org/10.1093/rheumatology/kev318.CrossRef

50.

Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology (Oxford). 2017;56(4):581–8. https://doi.org/10.1093/rheumatology/kew441.CrossRef

51.••

Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol. 2012;107(4):597-603. https://doi.org/10.1038/ajg.2011.399. Important manscript providing data supporting the etiology of fecal incontinence in SSc being associated with a neuropathy.

52.

Collins J, Mazor Y, Jones M, Kellow J, Malcolm A. Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study. Scand J Gastroenterol. 2016;51(12):1433–8. https://doi.org/10.1080/00365521.2016.1218537.CrossRefPubMed

53.

Al Asari S, Meurette G, Mantoo S, Kubis C, Wyart V, Lehur PA. Percutaneous tibial nerve stimulation vs sacral nerve stimulation for faecal incontinence: a comparative case-matched study. Color Dis. 2014;16(11):O393–9. https://doi.org/10.1111/codi.12680.CrossRef

54.

Butt SK, Alam A, Cohen R, Krogh K, Buntzen S, Emmanuel A. Lack of effect of sacral nerve stimulation for incontinence in patients with systemic sclerosis. Color Dis. 2015;17(10):903–7. https://doi.org/10.1111/codi.12969.CrossRef

55.••

Fernandez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm G. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820-8. https://doi.org/10.1002/art.40560. Updated treatment algorithms for managing SSc GI disease.

56.

Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55(12):1697–703. https://doi.org/10.1136/gut.2005.086074.CrossRefPubMedPubMedCentral

57.

Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol. 2018;24(6):328–37. https://doi.org/10.1097/RHU.0000000000000626.CrossRefPubMed

Titel: Managing Gastrointestinal Complications in Patients With Systemic Sclerosis
verfasst von: Z. H. McMahan, MD, MHS
D. Khanna, MBBS, MSc
Publikationsdatum: 13.11.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 4/2020
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-020-00314-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Managing Gastrointestinal Complications in Patients With Systemic Sclerosis

Abstract

Objective

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Nutritional Therapies for Irritable Bowel Syndrome: a Focus on Prebiotics and Probiotics

Who Needs Gastroprotection in 2020?

Biologic Therapy in Elderly Patients with IBD: Current Trends and Special Management Considerations

Management of Severe Acute Pancreatitis

Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations

Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin